Eli Lilly, the supplier of prasugrel tablets has stopped making this medicine. PHARMAC was unable to find another supplier.
On this page:
- About this discontinuation
- Information for people who take prasugrel
- Information for prescribers
- Key dates for prescribers and pharmacists
- Who to contact
About 65 people in New Zealand use prasugrel 5mg or 10mg tablets. Prasugrel is an antiplatelet medicine, which helps stop blood clots.
Supplies of prasugrel are likely to run out by the end of October 2020. You won’t be able to get prasugrel once the current supply runs out.
You will need to talk to your health care professional about an alternative to prasugrel. There are other treatment options available. Your health care professional knows you and will help you find the best alternative.
We know that changing medicines can be disruptive. We apologise for any inconvenience.
Prescribers will need to:
- ensure no new patients are started on prasugrel
- transition patients currently on prasugrel to alternative treatments as soon as possible.
Ticagrelor is an appropriate alternative
PHARMAC has received advice from the cardiovascular and haematology subcommittees of the Pharmacology and Therapeutics Advisory Committee (PTAC). These subcommitees are two of our expert clinical advisory groups.
The subcommittees advise that ticagrelor would be an appropriate alternative antiplatelet for these patients. Access to ticagrelor requires a Special Authority.
Access to ticagrelor
Before 1 September 2020: Existing prasugrel patients can access ticagrelor via Special Authority (SA) waiver. You cannot use the Online Special Authority system to request a waiver.
- Download the current SA form from the ticagrelor listing in the Schedule.
- Complete the form, indicating that the patient has been taking prasugrel
- Email the form to firstname.lastname@example.org
From 1 September 2020: The Special Authority criteria for ticagrelor will be widened to enable existing prasugrel patients access.
The Schedule will be updated from 1 September with the updated SA form.
- Before 1 September – Funded ticagrelor can be accessed for existing prasugrel patients via application to PHARMAC for a Special Authority waiver.
- 1 September 2020 – Ticagrelor Special Authority criteria widened to ensure existing prasugrel patients are eligible for funded access to this alternative.
- 30 October 2020 – Current stock of prasugrel expected to run out.
- 31 January 2021 – Existing stock of prasugrel in New Zealand expires.
- 31 January 2021 – Prasugrel delisted from the Pharmaceutical Schedule
If you have any questions about this discontinuation, contact PHARMAC on:
> Phone: 0800 66 00 50(external link)
> Email: email@example.com
Last updated: 26 August 2020